In this past year the phase 1/2a clinical trial has been completed with all 28 patients completing the trial. Database lock occurred on 08Nov17. The clinical study report is in progress.
Twenty-two (22) patients have been dosed in the phase 1/2a clinical trial extension study. There are 3 patients in observation and 3 patients that declined. To date the progenitor cell treatment has been well tolerated.
The first patient enrolled into the phase 2b clinical trial was 27Sep17.